Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events.

ABSTRACT:

Purpose

To describe serum vascular endothelial growth factor (sVEGF) in patients with neovascular age-related macular degeneration (nAMD) receiving anti-VEGF agents and associations between sVEGF and systemic serious adverse events (SSAEs).

Design

Exploratory analyses of a randomized controlled trial that enrolled 610 participants with nAMD and compared 2 anti-VEGF antibodies, ranibizumab and bevacizumab, and 2 treatment regimens, monthly vs. discontinuous, with 2 years' follow-up.

Participants

Adults aged 50+ years with treatment-naïve nAMD and a visual acuity of ≥25 letters (Snellen equivalent 20/320) in the affected eye.

Methods

Intravitreal injection of anti-VEGF antibodies.

Main outcome measures

sVEGF and occurrence of SSAE, with particular interest

SUBMITTER: Rogers CA 

PROVIDER: S-EPMC6278944 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature